| Medical and Health Sciences | Lifetime | 303 | US 167 | 99.99 |
| Epidemiology | Lifetime | 6 | US 4 | 99.99 |
| Infectious Diseases | Lifetime | 59 | US 31 | 99.80 |
| Virology | Lifetime | 15 | US 14 | 99.71 |
| Oncology | Lifetime | 745 | US 414 | 98.46 |
| Immunology | Lifetime | 857 | US 434 | 97.21 |
| Hepatology | Lifetime | 487 | US 160 | 95.07 |
| Microbiology | Lifetime | 554 | US 247 | 85.87 |
| Parasitology | Lifetime | 686 | US 276 | 84.17 |
| Infectious Diseases | 2021-2025 | 64 | US 20 | 99.03 |
| Virology | 2021-2025 | 5 | US 2 | 97.42 |
| Health | 2021-2025 | 309 | US 127 | 91.12 |
| Cytomegalovirus and herpesvirus research | Lifetime | 1 | US 1 | 99.98 |
| Herpesvirus Infections and Treatments | Lifetime | 1 | US 1 | 99.98 |
| Parvovirus B19 Infection Studies | Lifetime | 2 | US 1 | 99.98 |
| HIV Research and Treatment | Lifetime | 22 | US 19 | 99.87 |
| Viral-associated cancers and disorders | Lifetime | 34 | US 16 | 99.60 |
| COVID-19 Clinical Research Studies | Lifetime | 106 | US 27 | 99.34 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 112 | US 45 | 99.43 |
| Poxvirus research and outbreaks | Lifetime | 25 | US 20 | 99.05 |
| Urticaria and Related Conditions | Lifetime | 60 | US 22 | 99.20 |
| Virus-based gene therapy research | Lifetime | 213 | US 151 | 99.22 |
| vaccines and immunoinformatics approaches | Lifetime | 49 | US 31 | 99.22 |
| HIV/AIDS drug development and treatment | Lifetime | 190 | US 104 | 99.20 |
| Hepatitis B Virus Studies | Lifetime | 284 | US 104 | 99.16 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 114 | US 63 | 98.47 |
| Immune Cell Function and Interaction | Lifetime | 672 | US 358 | 99.13 |
| Respiratory viral infections research | Lifetime | 258 | US 142 | 98.91 |
| Genital Health and Disease | Lifetime | 113 | US 56 | 98.79 |
| Hepatitis Viruses Studies and Epidemiology | Lifetime | 99 | US 37 | 98.64 |
| HIV/AIDS Research and Interventions | Lifetime | 356 | US 214 | 99.07 |
| Hepatitis C virus research | Lifetime | 420 | US 137 | 98.79 |
| Dermatology and Skin Diseases | Lifetime | 246 | US 75 | 98.66 |
| Polyomavirus and related diseases | Lifetime | 148 | US 81 | 98.34 |
| Immunotherapy and Immune Responses | Lifetime | 779 | US 401 | 98.79 |
| Bartonella species infections research | Lifetime | 23 | US 14 | 97.79 |
| Reproductive tract infections research | Lifetime | 277 | US 152 | 97.65 |
| Syphilis Diagnosis and Treatment | Lifetime | 182 | US 92 | 96.45 |
| Systemic Lupus Erythematosus Research | Lifetime | 972 | US 329 | 97.34 |
| Toxoplasma gondii Research Studies | Lifetime | 270 | US 121 | 96.63 |
| Virology and Viral Diseases | Lifetime | 510 | US 245 | 96.28 |
| Vaccine Coverage and Hesitancy | Lifetime | 897 | US 405 | 95.19 |
| Infectious Encephalopathies and Encephalitis | Lifetime | 291 | US 114 | 92.01 |
| Acne and Rosacea Treatments and Effects | Lifetime | 418 | US 179 | 92.18 |
| Drug-Induced Adverse Reactions | Lifetime | 917 | US 277 | 90.92 |
| Rabies epidemiology and control | Lifetime | 947 | US 303 | 90.62 |
| HIV Research and Treatment | 2021-2025 | 17 | US 10 | 99.12 |
| COVID-19 Clinical Research Studies | 2021-2025 | 132 | US 41 | 99.25 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 156 | US 61 | 99.25 |
| HIV/AIDS drug development and treatment | 2021-2025 | 105 | US 35 | 96.05 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 387 | US 127 | 95.01 |
| vaccines and immunoinformatics approaches | 2021-2025 | 160 | US 38 | 92.22 |
| Herpesvirus Infections and Treatments | 2021-2025 | 262 | US 93 | 89.79 |
| HIV/AIDS Research and Interventions | 2021-2025 | 759 | US 379 | 93.63 |
